Effectivness of Topical Tacrolimus Monotherapy in Patients With Vitiligo

Status Recruiting

Clinical Trial Summary

The study will evaluate the effectiveness of Tacrolimus 0.03% ointment monotherapy in patients with vitiligo. Patients will be treated for 6 months and followed for 3 months after treatment. All types of vitiligo will be included.

Clinical Trial Description

Study approval: The study was submitted for approval by Scientific and Ethical Committee at Faculty of Medicine, Sohag University. An informed written consent will be obtained from all participants.

Study design: randomized controlled trial. Study population: the study will include patients who attend the outpatient Clinic of Dermatology & Venereology and Andrology, Faculty of Medicine, Sohag University in corporation with Farshot General Hospital. Women who are pregnant or lactating, children aged 2 years or less and patients with acute or chronic disease that might affect skin barrier function will be excluded.

Patients and methods:

Study participants will be randomly divided into two treatment groups: group A will receive 0.03% tacrolimus ointment and group B will receive hydrocortisone acetate 1% ointment twice daily for 6 months.

Patients will be evaluated at baseline and monthly intervals for 6 months and at 3 months after stopping treatment. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03358082
Study type	Interventional
Source	Sohag University
Contact	Aml Ahmed, MBBCH
Phone	01093801703
Email	hanodymody12@gmail.com
Status	Recruiting
Phase	Phase 1/Phase 2
Start date	October 1, 2017
Completion date	February 1, 2019

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT05298033` - Study of Efficacy, Safety and Tolerability of Crisaborole and PF-07038124 With and Without NBUVB in Vitiligo	Phase 2
Recruiting	`NCT05872477` - Promoting Repigmentation After Epidermal Cell Suspension Grafting and preVENTing the Loss of Melanocytes Using Topical Ruxolitinib for Vitiligo in Resistant Areas	Phase 2
Terminated	`NCT04374435` - Evaluating the Efficacy of the Melanocyte Keratinocyte Transplantation Procedure in the Treatment of Vitiligo	N/A
Completed	`NCT04103060` - Safety and Tolerability Study of Cerdulatinib Gel, 0.37% in Adults With Vitiligo	Phase 2
Terminated	`NCT04271501` - Feasibility Study to Evaluate RECELL and Melanocyte Keratinocyte Transplantation Procedure for Repigmentation of Stable Vitiligo Lesions	N/A
Completed	`NCT04530344` - Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo	Phase 3
Not yet recruiting	`NCT05008887` - Fractional CO2 Laser-assisted Cutaneous Delivery of Methotrexate Versus 5-fluorouracil in Stable Non-segmental Vitiligo	Phase 4
Terminated	`NCT02191748` - Assessing the Efficacy of Needling With or Without Corticosteroids in the Repigmentation of Vitiligo	Phase 2/Phase 3
Completed	`NCT01382589` - Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo	Phase 2
Terminated	`NCT01262547` - A New Micrografting Technique for Vitiligo	Phase 2
Active, not recruiting	`NCT04971200` - Pilot Study Assessing the Effect of Tildrakizumab in Vitiligo	Early Phase 1
Completed	`NCT04872257` - Oral Vitamin D Supplementation Combined With Phototherapy as a Treatment for Vitiligo	N/A
Completed	`NCT04547998` - Clinical Study to Investigate the Safety and Effectiveness of RECELL for Repigmentation of Stable Vitiligo Lesions	N/A
Not yet recruiting	`NCT04039451` - Prevalence of Psoriasis and Vitiligo in Assiut Governorate, Egypt
Not yet recruiting	`NCT03611348` - Microneedling and Latanoprost in Acrofacial Vitiligo	Phase 2/Phase 3
Recruiting	`NCT03199664` - Effectiveness of Narrow-band Ultraviolet B Combined With Topical Tacrolimus 0.03% in Treatment of Patients With Vitiligo	Phase 4
Recruiting	`NCT03340155` - Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases	N/A
Completed	`NCT03249064` - Response to Tregs in Innate Immunity Receptor LRP1 (CD91) and Tregs in Periferic Blood Mononuclear Cells in Patients With Non-segmentary Vitiligo	N/A
Recruiting	`NCT05635266` - A Single-Site Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Recruiting	`NCT04246372` - Tofacitinib for Immune Skin Conditions in Down Syndrome	Phase 2